VIR Vir Biotechnology, Inc.
Vir Biotechnology, Inc. engages in the provision of technologies to treat and prevent infectious diseases. Its technology platforms include antibody, T cell, innate immunity, and siRNA. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in 2016 and is headquartered in San Francisco, CA.
$45.17 +5.50 (13.85%)
As of 03/05/2021 15:59:55 EST IEX book CBOE book
Security Information
Category1:
Category2:
Category3:
GICS sector:
Industry:
Index country:
Country of incorporation:
IPO date:
Outstanding shares:
Average volume:
Market cap:
Current dividend yield:
All SEC filings:
Quarterly filings:
Annual filings:
CUSIP:
ISIN:
Sedol:
Category2:
Category3:
GICS sector:
Industry:
Index country:
Country of incorporation:
IPO date:
Outstanding shares:
Average volume:
Market cap:
Current dividend yield:
All SEC filings:
Quarterly filings:
Annual filings:
CUSIP:
ISIN:
Sedol:
US Equity
Common stocks
Mid cap
Health Care
Biotechnology
USA
USA
12/16/2013
127,836,816
1,425,467
$5,071,286,491
0.00%
SEC Edgar Online
10-Q
10-K
92764N102
US92764N1028
BK4PZ38
Common stocks
Mid cap
Health Care
Biotechnology
USA
USA
12/16/2013
127,836,816
1,425,467
$5,071,286,491
0.00%
SEC Edgar Online
10-Q
10-K
92764N102
US92764N1028
BK4PZ38
Valuation (See tab for details)
PE ratio:
PB ratio:
PS ratio:
Return on equity:
Net income %:
PB ratio:
PS ratio:
Return on equity:
Net income %:
-19.75
7.07
67.07
-35.82%
-339.60%
7.07
67.07
-35.82%
-339.60%